Akèy › Limfòm Non-Hodgkin › Minnesota › Rochester
Etid klinik pou Limfòm Non-Hodgkin nan Rochester, MN
14 etid pou Limfòm Non-Hodgkin ap chèche patisipan nan sit nan ak bò kote Rochester (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Ap rekriteFaz 1/2
- Mayo Clinic Rochester, Rochester
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- Mayo Clinic - Rochester, Rochester
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Ap rekriteFaz 1
- Mayo Clinic - Rochester, Rochester
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Ap rekriteFaz 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Ap rekriteFaz 2
- Research Site, Rochester
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1/2
- Research Site, Rochester
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Ap rekriteFaz 1/2
- Mayo Clinic, Clinical Trials Referral Office, Rochester
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Mayo Clinic Rochester, Rochester
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Mayo Clinic, Rochester
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- Mayo Clinic, Rochester
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Mayo Clinic, Rochester
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Ap rekriteFaz 4
- Mayo Clinic- Minnesota, Rochester
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Ap rekriteFaz 4
- Mayo Clinic- Minnesota, Rochester
Family Study of Lymphoproliferative Disorders
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Mayo Clinic, Rochester
Etid Limfòm Non-Hodgkin nan lòt vil
- New York City, NY31 etid
- Houston, TX31 etid
- Boston, MA26 etid
- Nashville, TN21 etid
- Philadelphia, PA20 etid
- Baldwin Park, CA19 etid
- Washington, DC18 etid
- Chicago, IL18 etid
- Milwaukee, WI18 etid
- Atlanta, GA18 etid
- Columbus, OH18 etid
- Dallas, TX17 etid
Lòt etid nan Rochester
- Kansè nan tete42 etid
- Kansè Poumon ki pa ti selil37 etid
- Kansè Metastatik31 etid
- Kansè (tout kalite)30 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Myelom Miltip24 etid
- Ensifizyans kadyak22 etid
- Kansè pwostat22 etid
- Kansè pankreyas22 etid
- Kansè Endomèt20 etid
- Kansè poumon20 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.